Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners
This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about t
- PDF / 2,106,458 Bytes
- 122 Pages / 439.42 x 683.15 pts Page_size
- 91 Downloads / 171 Views
123
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners
Marianne Davies • Beth Eaby-Sandy Editors
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners
Editors Marianne Davies Yale Comprehensive Cancer Center Yale University School of Nursing New Haven, CT USA
Beth Eaby-Sandy Abramson Cancer Center University of Pennsylvania Philadelphia, PA USA
ISBN 978-3-030-16549-9 ISBN 978-3-030-16550-5 (eBook) https://doi.org/10.1007/978-3-030-16550-5 © Springer Nature Switzerland AG 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Contents
1 Introduction������������������������������������������������������������������������������������������������ 1 Beth Eaby-Sandy 2 Introduction to Mutation Testing ������������������������������������������������������������ 3 Vanna Dest and Kathryn Medow 3 Nursing Considerations with EGFR Inhibitors in NSCLC ������������������ 17 Michelle M. Turner and Beth Eaby-Sandy 4 Nursing Considerations with ALK and ROS1 Inhibitors in NSCLC���������������������������������������������������������������������������������������������������� 27 Beth Eaby-Sandy 5 BRAF in NSCLC���������������������������������������������������������������������������������������� 39 Helen Shih 6 Mechanisms of Acquired Resistance to Targeted Therapy in NSCLC: Role of Repeat Biopsy and Nursing Considerations���������� 51 Emily Duffield 7 The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer�������������������������������������������������������������� 65 Stephanie Crawford Andrews and Marianne Davies 8 The Role of Anti-Angiogenic Agents (VEGF)����������������������
Data Loading...
